Shunsuke Nakae, Masanobu Kumon, Kazuhiro Murayama, Shigeo Ohba, Hikaru Sasaki, Joji Inamasu, Kiyonori Kuwahara, Seiji Yamada, Masato Abe, Yuichi Hirose
Scientific Reports, 11(1) 7927-7927, Dec, 2021 Peer-reviewed
<title>Abstract</title>Seizures are common in patients with gliomas; however, the mechanisms of epileptogenesis in gliomas have not been fully understood. This study hypothesized that analyzing quantified metabolites using magnetic resonance spectroscopy (MRS) might provide novel insights to better understand the epileptogenesis in gliomas, and specific metabolites might be indicators of preoperative seizures in gliomas. We retrospectively investigated patient information (gender, age at diagnosis of tumor, their survival time) and tumor information (location, histology, genetic features, and metabolites according to MRS) in patients with gliomas. The data were correlated with the incidence of seizure and analyzed statistically. Of 146 adult supratentorial gliomas, <italic>isocitrate dehydrogenase</italic> (<italic>IDH</italic>) mutant tumors significantly indicated higher incidence of preoperative seizures than <italic>IDH</italic> wild-type gliomas. However, MRS study indicated that glutamate concentration in <italic>IDH</italic> wild-type gliomas was higher than that in <italic>IDH</italic> mutant gliomas. Glutamate was not associated with high frequency of preoperative seizures in patients with gliomas. Instead, increased total <italic>N</italic>-acetyl-<sc>l</sc>-aspartate (tNAA) was significantly associated with them. Moreover, multivariable analysis indicated that increased level of tNAA was an independent predictor of preoperative seizures. According to MRS analysis, tNAA, rather than glutamate, might be a useful to detect preoperative seizures in patient with supratentorial gliomas.